Lineage Cell Therapeutics (LCTX) Change in Cash (2010 - 2026)

Lineage Cell Therapeutics' Change in Cash history runs 17 years deep, the most recent figure standing at -$4.8 million for Q1 2026.

• On a quarterly basis, Change in Cash fell 343.86% year-over-year to -$4.8 million in Q1 2026; TTM through Mar 2026 was -$11.9 million, a 381.18% decrease from a year earlier, with the FY2025 full-year figure at -$5.0 million, down 148.54% from the prior year.
• Change in Cash eased to -$4.8 million in Q1 2026 per LCTX's latest filing, from $347000.0 in the prior quarter.
• Across five years, Change in Cash topped out at $22.3 million in Q1 2022 and bottomed at -$46.1 million in Q3 2022.
• The 5-year median for Change in Cash is -$1.8 million (2025), against an average of -$1.2 million.
• Across the five-year window, Change in Cash tumbled 3777.44% in 2022 and surged 354.34% in 2023, its largest moves.
• Year by year, Change in Cash stood at -$13.4 million in 2022, then jumped by 129.88% to $4.0 million in 2023, then soared by 352.1% to $18.0 million in 2024, then slumped by 98.08% to $347000.0 in 2025, then plunged by 1497.12% to -$4.8 million in 2026.
• Per Business Quant, the three latest LCTX Change in Cash figures stand at -$4.8 million (Q1 2026), $347000.0 (Q4 2025), and -$1.8 million (Q3 2025).